CDMA presents awards at annual trade expo
NEW ORLEANS The Chain Drug Marketing Association last week awarded Brookshire Brothers as the Grocery Retail Chain of the Year at its 83rd Annual Education & Trade Expo.
Other awards presented included:
- Klingensmith’s Drug Stores for Small Retail Chain of the Year;
- Blake Pharmacy for Independent Pharmacy of the Year;
- Value Drug for Wholesaler of the Year;
- PL Development for QC Supplier of the Year;
- Evans Drug for Member of the Year;
- Art Pirrone for Associate Member of the Year; and
- Bill Earnest received the Chairman’s Award for his service and contribution from 2007-2009.
New additions to the association’s board included Lanny Doud of Rochester Drug Cooperative and Karla Moschella of Value Drug Company. Jack Walker, of Walker Drug, was elected chairman for the 2009-2011 term. Walker’s mission for CDMA is to promote product sourcing with the new Everyday Essentials program, which provides more than 5,000 hard-to-source SKUs across all categories.
The CDMA 84th Education & Trade Expo will be held in Chicago March 16-18, 2010.
Merck, Cardiome Pharma to collaborate, develop atrial fibrillation treatment
VANCOUVER, B.C. Merck & Co. and Cardiome Pharma Corp. announced this week that they would collaborate to develop and commercialize a drug being investigated as a treatment for atrial fibrillation.
The agreement provides Merck with exclusive global rights to the oral formulation of vernakalant, designed for the maintenance of normal heart rhythm in patients with atrial fibrillation. It also provides Merck with exclusive rights outside North America for an intravenous formulation of the drug used for rapid treatment of the disease.
“This agreement underscores Merck’s ongoing commitment to the research and development of new cardiovascular drugs,” Merck Research Laboratories SVP and franchise head of atherosclerosis and cardiovascular Luciano Rossetti said. “Vernakalant is an important addition to our broad portfolio of products and candidates that target multiple aspects of heart disease.”
FDA approves new topical treatment of head lice
ROCKVILLE, Md. The Food and Drug Administration has approved a new prescription topical medication for treating head lice, the agency announced Thursday.
Sciele Pharma’s Benzyl Alcohol Lotion, 5% is the first head lice treatment approved by the FDA that uses benzyl alcohol as its active pharmaceutical ingredient. It is meant for patients ages 6 months and older.
“Head lice are a problem that impacts more than 1 million children each year and is easily transmitted to others,” FDA Center for Drug Evaluation and Research director Janet Woodcock said. “This drug is an effective first-line treatment to eliminate lice infestation and minimize disruption in the daily routines of families.”